Modulation of angiogenesis by dithiolethione-modified NSAIDs and valproic acid

British Journal of Pharmacology

Volumn 151, Issue 1, 2007, Pages 142-151

  Isenberg, J S ^a   Jia, Y ^a   Field, L ^a   Ridnour, L A ^a   Sparatore, A ^b   Del Soldato, P ^c   Sowers, A L ^a   Yeh, G C ^d   Moody, T W ^a   Wink, D A ^a   Ramchandran, R ^a   Roberts, D D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF MILAN   (Italy)

^c CTG Pharma   (Italy)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Angiogenesis inhibitors; Dithioles; hsp27 phosphorylation; Nonsteroidal anti inflammatory drugs

Indexed keywords

2 PROPYLPENTANOIC ACID 4 (5 THIOXO 5H 1,2 DITHIOL 3 YL)PHENYL ESTER; 2 [(2,6 DICHLOROPHENYL)AMINO]BENZENEACETIC 4 (5 THIOXO 5H 1,2 DITHIOL 3 YL)PHENYL ESTER; 5 FLUORO 2 METHYL 1 [[4 (METHYLSULFINYL)PHENYL]METHYLENE] 1H INDENE 3 ACETIC ACID 4 (THIOXO 5H [1,2]DITHIOL 3 YL)PHENYL ESTER; ANGIOGENESIS INHIBITOR; DICLOFENAC DERIVATIVE; DITHIOL DERIVATIVE; GREEN FLUORESCENT PROTEIN; HYDROGEN SULFIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; SULINDAC; TRANSCRIPTION FACTOR FLI 1; UNCLASSIFIED DRUG; VALPROIC ACID; VALPROIC ACID DERIVATIVE;

ANGIOGENESIS; ANIMAL CELL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL PROLIFERATION; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG MECHANISM; DRUG POTENCY; DRUG TARGETING; EMBRYO; ENDOTHELIUM CELL; ENZYME INHIBITION; HUMAN; HUMAN CELL; MUSCLE TISSUE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSGENIC ANIMAL; UMBILICAL VEIN; ZEBRA FISH;

EID: 34247595399     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707198     Document Type: Article

References (36)

1. Arrigo AP, Virot S, Chaufour S, Firdaus W, Kretz-Remy C, Diaz-Latoud C (2005). Hsp27 consolidates intracellular redox homeostasis by upholding glutathione in its reduced form and by decreasing iron intracellular levels. Antioxid Redox Signal 7: 414-422.
2. Ben-Mahdi MH, Gozin A, Driss F, Andrieu V, Christen MO, Pasquier C (2000). Anethole dithiolethione regulates oxidant-induced tyrosine kinase activation in endothelial cells. Antioxid Redox Signal 2: 789-799.
3. Bhatia M, Sidhapuriwala JAS, Moore PK (2005). Treatment with H2S-releasing derivative of diclofenac reduces inflammation in carrageenan-induced hindpaw oedema. Inflammation Res (Suppl. a): S185.
4. Bix G, Fu J, Gonzalez EM, Macro L, Barker A, Campbell S et al. (2004). Endorepellin causes endothelial cell disassembly of actin cytoskeleton and focal adhesions through alpha2beta1 integrin. J Cell Biol 166: 97-109.
5. Bottcher B, Bauer F, Trithiones V (1951). Some new trithiones. Chemische Berichte 84: 458-463.
6. Butt E, Immler D, Meyer HE, Kotlyarov A, Laass K, Gaestel M (2001). Heat shock protein 27 is a substrate of cGMP-dependent protein kinase in intact human platelets: phosphorylation-induced actin polymerization caused by HSP27 mutants. J Biol Chem 276: 7108-7113.
7. Cao Y (2005). Tumor angiogenesis and therapy. Biomed Pharmacother 59: S340-S343.
8. Carmeliet P (2004). Manipulating angiogenesis in medicine. J Intern Med 255: 538-561.
9. Carmeliet P (2005). Angiogenesis in life, disease and medicine. Nature 438: 932-936.
10. Distrutti E, Sediari L, Mencarelli A, Renga B, Orlandi S, Russo G et al. (2006). 5-Amino-2-hydroxybenzoic acid 4-(5-thioxo-5H-[1,2]dithiol-3yl)- phenyl ester (ATB-429), a hydrogen sulfide-releasing derivative of mesalamine, exerts antinociceptive effects in a model of postinflammatory hypersensitivity. J Pharmacol Exp Ther 319: 447-458.
11. Elwich-Flis S, Soltysiak-Pawluczuk D, Splawinski J (2003). Antiangiogenic and apoptotic effects of metabolites of sulindac on chick embryo chorioallantoic membrane. Hybrid Hybridomics 22: 55-60.
12. Ferrara N, Kerbel RS (2005). Angiogenesis as a therapeutic target. Nature 438: 967-974.
13. Flis S, Soltysiak-Pawluczuk D, Jedrych A, Jastrzebski Z, Remiszewska M, Splawinski J (2006). Antiangiogenic effect of sulindac sulfide could be secondary to induction of apoptosis and cell cycle arrest. Anticancer Res 26: 3033-3041.
14. Folkman J (2006). Angiogenesis. Annu Rev Med 57: 1-18.
15. Gately S, Li WW (2004). Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Semin Oncol 31: 2-11.
16. Gourzoulidou E, Carpintero M, Baumhof P, Giannis A, Waldmann H (2005). Inhibition of angiogenesis-relevant receptor tyrosine kinases by sulindac analogues. Chembiochem 6: 527-531.
17. Isenberg JS, Ridnour LA, Perruccio EM, Espey MG, Wink DA, Roberts DD (2005). Thrombospondin-1 inhibits endothelial cell responses to nitric oxide in a cGMP-dependent manner. Proc Natl Acad Sci USA 102: 13141-13146.
18. Keezer SM, Ivie SE, Krutzsch HC, Tandle A, Libutti SK, Roberts DD (2003). Angiogenesis inhibitors target the endothelial cell cytoskeleton through altered regulation of heat shock protein 27 and cofilin. Cancer Res 63: 6405-6412.
19. Kensler T, Styczynski P, Groopman J, Helzlsouer K, Curphey T, Maxuitenko Y et al. (1992). Mechanisms of chemoprotection by oltipraz. J Cell Biochem Suppl 16I: 167-172.
20. Kensler TW, Curphey TJ, Maxiutenko Y, Roebuck BD (2000). Chemoprotection by organosulfur inducers of phase 2 enzymes: dithiolethiones and dithiins. Drug Metabol Drug Interact 17: 3-22.
21. Kwak MK, Egner PA, Dolan PM, Ramos-Gomez M, Groopman JD, Itoh K et al. (2001). Role of phase 2 enzyme induction in chemoprotection by dithiolethiones. Mutat Res 480-481: 305-315.
22. Landry J, Huot J (1999). Regulation of actin dynamics by stress-activated protein kinase 2 (SAPK2)-dependent phosphorylation of heat-shock protein of 27 kDa (Hsp27). Biochem Soc Symp 64: 79-89.
23. Lawson ND, Weinstein BM (2002). In vivo imaging of embryonic vascular development using transgenic zebrafish. Dev Bio 248: 307-318.
24. Lee JS, Surh YJ (2005). Nrf2 as a novel molecular target for chemoprevention. Cancer Lett 224: 171-184.
25. Li L, Rossoni G, Sparatore A, Lee L, Del Soldato P, Moore P (2006). Anti-inflammatory and gatrointestinal sparing activity of a novel H2S-releasing diclofenac agent: new insights into the biological roles of H2S. Free Radic Biol Med 42: 706-719.
26. Michaelis M, Michaelis UR, Fleming I, Suhan T, Cinatl J, Blaheta RA et al. (2004). Valproic acid inhibits angiogenesis in vitro and in vivo. Mol Pharmacol 65: 520-527.
27. Nguyen A, Chen P, Cai H (2004). Role of CaMKII in hydrogen peroxide activation of ERK1/2, p38 MAPK, HSP27 and actin reorganization in endothelial cells. FEBS Lett 572: 307-313.
28. Ong MM, Sparatore A, del Soldato P, Moore PK, Treinen-Moslen M, Boelsterli UA (2006). Differential covalent adduct biodistribution of diclofenac and a diclofenac sulfurated ester in rat liver and small intestine. The Toxicologist S2136: 438.
29. Ruggeri BA, Robinson C, Angeles T, Wilkinson J, Clapper ML (2002). The chemopreventive agent oltipraz possesses potent antiangiogenic activity in vitro, ex vivo, and in vivo and inhibits tumor xenograft growth. Clin Cancer Res 8: 267-274.
30. Sharma S, Ghoddoussi M, Gao P, Kelloff GJ, Steele VE, Kopelovich L (2001). A quantitative angiogenesis model for efficacy testing of chemopreventive agents. Anticancer Res 21: 3829-3837.
31. Thomas DD, Espey MG, Ridnour LA, Hofseth LJ, Mancardi D, Harris CC et al. (2004). Hypoxic inducible factor 1alpha, extracellular signal-regulated kinase, and p53 are regulated by distinct threshold concentrations of nitric oxide. Proc Natl Acad Sci USA 101: 8894-8899.
32. Ulrich CM, Bigler J, Potter JD (2006). Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer 6: 130-140.
33. Verheul HM, Pinedo HM (2005). Angiogenesis inhibitors: what is the clinical future? Prog Drug Res 63: 67-91.
34. Westerfield M (2000). The Zebrafish Book. University of Oregon Press, Eugene, Oregon, p363.
35. Yao KS, O'Dwyer PJ (2003). Role of the AP-1 element and redox factor-1 (Ref-1) in mediating transcriptional induction of DT-diaphorase gene expression by oltipraz: a target for chemoprevention. Biochem Pharmacol 66: 15-23.
36. Zgouras D, Becker U, Loitsch S, Stein J (2004). Modulation of angiogenesis-related protein synthesis by valproic acid. Biochem Biophys Res Commun 316: 693-697.